Emmanuel Antonarakis, MD
Associate Director, Translational Research
United States
Administrative support contact for Dr. Antonarakis: Heidi Goski
Dr. Antonarakis is the Clark Endowed Professor of Medicine, and a genitourinary medical oncologist with a particular focus on recurrent and advanced prostate cancer. He conducts clinical and translational studies to bring new therapies to patients with prostate cancer. In particular, he is interested in developing novel androgen-directed therapies, genetically-targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, and using germline and tumor genomics to inform precision oncology approaches for these patients. He also has an interest in liquid biomarker development, including the clinical validation of the AR-V7 marker as well as DNA repair markers and their therapeutic implications. He is also involved in mentoring fellows and junior faculty in the clinical care of genitourinary cancers and the development of translational research strategies related to prostate cancer.
Education
Medical School, University of Wales College of Medicine, Cardiff, Wales,
UK Internship, University Hospital of Wales, Cardiff, Wales,
UK Residency in Internal Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD
Fellowship in Medical Oncology, Johns Hopkins Hospital, Baltimore, MD
Awards & Recognitions
Elected to membership in the American Society of Clinical Investigation, April 2022
Research
Research Summary/Interests
Prostate Cancer Clinical and Translational Research; Liquid Biopsy in Cancer; Genetics and Genomics; Cancer Immunotherapy; Androgen-Directed Therapies; Genetically-Targeted Therapies; Biomarker Development; Precision Oncology
Clinical
Clinical Information
Board Certified Medical Oncologist specializing in genitourinary oncology, particularly recurrent and advanced prostate cancer
Where Dr. Antonarakis Sees Patients:
Masonic Cancer Center